Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Patricia Keegan

Showing results (1-10 of 120) with videos related to

Pageof 12
Sort By:
The New England Journal of Medicine|October 12, 2017
First FDA Approval Agnostic of Cancer Site - When a Biomarker Defines the IndicationSteven Lemery, Patricia Keegan, Richard Pazdur
The Oncologist|February 29, 2008
FDA drug approval summary: alemtuzumab as single-agent treatment for B-cell chronic lymphocytic leukemiaSuzanne Demko, Jeffrey Summers, Patricia Keegan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 22, 2019
FDA Approval Summary: Pembrolizumab for the Treatment of Microsatellite Instability-High Solid TumorsLeigh Marcus, Steven J Lemery, Patricia Keegan, et al.
The Oncologist|January 12, 2010
FDA drug approval summary: bevacizumab plus interferon for advanced renal cell carcinomaJeff Summers, Martin H Cohen, Patricia Keegan, et al.
The Oncologist|April 5, 2007
FDA drug approval summary: bevacizumab plus FOLFOX4 as second-line treatment of colorectal cancerMartin H Cohen, Joe Gootenberg, Patricia Keegan, et al.
The Oncologist|July 3, 2007
FDA drug approval summary: bevacizumab (Avastin) plus Carboplatin and Paclitaxel as first-line treatment of advanced/metastatic recurrent nonsquamous non-small cell lung cancerMartin H Cohen, Joe Gootenberg, Patricia Keegan, et al.
Neuro-Oncology Practice|October 4, 2019
Clinical outcome assessments in neuro-oncology: a regulatory perspectiveJoohee Sul, Paul G Kluetz, Elektra J Papadopoulos, et al.
Journal of the National Cancer Institute|October 21, 2004
Accelerated approval of oncology products: a decade of experienceRamzi Dagher, John Johnson, Grant Williams, et al.
The Oncologist|November 10, 2009
FDA drug approval summary: bevacizumab (Avastin) as treatment of recurrent glioblastoma multiformeMartin H Cohen, Yuan Li Shen, Patricia Keegan, et al.
The Oncologist|March 14, 2009
FDA review of a panitumumab (Vectibix) clinical trial for first-line treatment of metastatic colorectal cancerRuthann M Giusti, Martin H Cohen, Patricia Keegan, et al.
Pageof 12

Showing results (1-10 of 120) with videos related to

Sort By:
Pageof 12
The New England Journal of Medicine|October 12, 2017
First FDA Approval Agnostic of Cancer Site - When a Biomarker Defines the IndicationSteven Lemery, Patricia Keegan, Richard Pazdur
The Oncologist|February 29, 2008
FDA drug approval summary: alemtuzumab as single-agent treatment for B-cell chronic lymphocytic leukemiaSuzanne Demko, Jeffrey Summers, Patricia Keegan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 22, 2019
FDA Approval Summary: Pembrolizumab for the Treatment of Microsatellite Instability-High Solid TumorsLeigh Marcus, Steven J Lemery, Patricia Keegan, et al.
The Oncologist|January 12, 2010
FDA drug approval summary: bevacizumab plus interferon for advanced renal cell carcinomaJeff Summers, Martin H Cohen, Patricia Keegan, et al.
The Oncologist|April 5, 2007
FDA drug approval summary: bevacizumab plus FOLFOX4 as second-line treatment of colorectal cancerMartin H Cohen, Joe Gootenberg, Patricia Keegan, et al.
The Oncologist|July 3, 2007
FDA drug approval summary: bevacizumab (Avastin) plus Carboplatin and Paclitaxel as first-line treatment of advanced/metastatic recurrent nonsquamous non-small cell lung cancerMartin H Cohen, Joe Gootenberg, Patricia Keegan, et al.
Neuro-Oncology Practice|October 4, 2019
Clinical outcome assessments in neuro-oncology: a regulatory perspectiveJoohee Sul, Paul G Kluetz, Elektra J Papadopoulos, et al.
Journal of the National Cancer Institute|October 21, 2004
Accelerated approval of oncology products: a decade of experienceRamzi Dagher, John Johnson, Grant Williams, et al.
The Oncologist|November 10, 2009
FDA drug approval summary: bevacizumab (Avastin) as treatment of recurrent glioblastoma multiformeMartin H Cohen, Yuan Li Shen, Patricia Keegan, et al.
The Oncologist|March 14, 2009
FDA review of a panitumumab (Vectibix) clinical trial for first-line treatment of metastatic colorectal cancerRuthann M Giusti, Martin H Cohen, Patricia Keegan, et al.
Pageof 12